Carboplatin 10 mg/ml Concentrate for Solution for Infusion clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3000-02-005/213357) Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination- Deficient Stage III/IV Ovarian Cancer
This study looks at new ways to treat advanced ovarian cancer before surgery. It compares a drug called niraparib with standard chemotherapy. Researchers want to see if the new approach is safer and works better for certain types of ovarian cancer.
For: Ovarian NeoplasmsSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
For: Non-small Cell Lung CancerCzechia · Poland · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
For: Non-small Cell Lung CancerFrance · Poland · Ireland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
This study is looking for new treatment combinations for head and neck cancer that has come back or spread. It's a Phase 2 trial, meaning researchers want to see how well these new drug combinations work and if they are safe.
For: Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaItaly · Spain · France - AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma - PERSEPHONE Trial
This study looks at a new combination of medicines (chemotherapy with a drug called tislelizumab) for people with a certain type of mouth cancer that can be removed with surgery. We want to see how well this combination shrinks the tumour before surgery.
For: Resectable Locally Advanced Oral Cavity Squamous Cell CarcinomaItaly